{"name":"Recordati","slug":"recordati","ticker":"REC.MI","exchange":"Borsa Italiana","domain":"recordati.com","description":"Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; ","hq":"Milan, Italy","founded":1926,"employees":"4614","ceo":"Rob Sobotka","sector":"Rare Disease / Specialty Pharma","stockPrice":49.18,"stockChange":0.06,"stockChangePercent":0.12,"marketCap":"$10.0B","metrics":{"revenue":2618383104,"revenueGrowth":10.7,"grossMargin":70.8,"rdSpend":0,"netIncome":443624000,"cash":428824000,"dividendYield":2.84,"peRatio":23.2,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Carbaglu","genericName":"CARGLUMIC ACID","slug":"carglumic-acid","revenue":200000000,"yoyGrowth":0,"percentOfTotal":50},{"name":"Isturisa","genericName":"OSILODROSTAT","slug":"osilodrostat","revenue":200000000,"yoyGrowth":0,"percentOfTotal":50}],"timeline":[{"date":"1949-01-01","label":"Valchlor first approved","drug":"Valchlor","drugSlug":"mechlorethamine","type":"approval","sentiment":"positive"},{"date":"1957-01-01","label":"Peganone first approved","drug":"Peganone","drugSlug":"ethotoin","type":"approval","sentiment":"positive"},{"date":"1964-01-01","label":"Cosmegen first approved","drug":"Cosmegen","drugSlug":"dactinomycin","type":"approval","sentiment":"positive"},{"date":"1996-01-01","label":"Cystadane first approved","drug":"Cystadane","drugSlug":"betaine","type":"approval","sentiment":"positive"},{"date":"2010-01-01","label":"Carbaglu first approved","drug":"Carbaglu","drugSlug":"carglumic-acid","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Signifor first approved","drug":"Signifor","drugSlug":"pasireotide","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Isturisa first approved","drug":"Isturisa","drugSlug":"osilodrostat","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Plicapon patent cliff ($15.6M at risk)","drug":"Plicapon","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Nuvigil patent cliff ($100.0M at risk)","drug":"Nuvigil","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":400000000,"percentOfTotal":100,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Carbaglu","genericName":"CARGLUMIC ACID","slug":"carglumic-acid","indication":"Hyperammonemia associated with N-acetylglutamate synthase deficiency","status":"marketed","revenue":200000000},{"name":"Isturisa","genericName":"OSILODROSTAT","slug":"osilodrostat","indication":"Hypercortisolism","status":"marketed","revenue":200000000},{"name":"Signifor","genericName":"PASIREOTIDE","slug":"pasireotide","indication":"Hypercortisolism","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Cosmegen","genericName":"DACTINOMYCIN","slug":"dactinomycin","indication":"Wilms Tumor","status":"marketed"},{"name":"Valchlor","genericName":"MECHLORETHAMINE","slug":"mechlorethamine","indication":"Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Cystadane","genericName":"BETAINE","slug":"betaine","indication":"Bacterial urinary infection","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"ENJAYMO","genericName":"SUTIMLIMAB-JOME","slug":"sutimlimab-jome","indication":"Cold autoimmune hemolytic anemia","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Peganone","genericName":"ETHOTOIN","slug":"ethotoin","indication":"Epilepsy characterized by intractable complex partial seizures","status":"marketed"}]}],"pipeline":[{"name":"Carbaglu","genericName":"CARGLUMIC ACID","slug":"carglumic-acid","phase":"marketed","mechanism":"Carbaglu works by activating the enzyme carbamoyl phosphate synthetase 1, which helps regulate ammonia levels in the body.","indications":["Hyperammonemia associated with N-acetylglutamate synthase deficiency"],"catalyst":""},{"name":"Isturisa","genericName":"OSILODROSTAT","slug":"osilodrostat","phase":"marketed","mechanism":"Isturisa blocks the production of cortisol in the adrenal glands by inhibiting the cytochrome P450 11B2 enzyme.","indications":["Hypercortisolism","Pituitary-dependent Cushing's disease"],"catalyst":""},{"name":"Cosmegen","genericName":"DACTINOMYCIN","slug":"dactinomycin","phase":"marketed","mechanism":"Dactinomycin binds DNA and inhibits RNA synthesis, demonstrating cytotoxic activity in cancer models.","indications":["Wilms Tumor","Rhabdomyosarcoma","Ewing Sarcoma","Metastatic Nonseminomatous Testicular Cancer","Gestational Trophoblastic Neoplasia"],"catalyst":""},{"name":"Valchlor","genericName":"MECHLORETHAMINE","slug":"mechlorethamine","phase":"marketed","mechanism":"Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death.","indications":["Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma"],"catalyst":""},{"name":"Cystadane","genericName":"BETAINE","slug":"betaine","phase":"marketed","mechanism":"Small molecule","indications":["Bacterial urinary infection","Complicated Proteus UTI","Complicated UTI with Pseudomonas Aeruginosa","Cystitis","E. Coli Pyelonephritis"],"catalyst":""},{"name":"ENJAYMO","genericName":"SUTIMLIMAB-JOME","slug":"sutimlimab-jome","phase":"marketed","mechanism":"Complement C1s subcomponent","indications":["Cold autoimmune hemolytic anemia"],"catalyst":""},{"name":"Peganone","genericName":"ETHOTOIN","slug":"ethotoin","phase":"marketed","mechanism":"Sodium channel alpha subunit","indications":["Epilepsy characterized by intractable complex partial seizures","Tonic-clonic epilepsy"],"catalyst":""},{"name":"Signifor","genericName":"PASIREOTIDE","slug":"pasireotide","phase":"marketed","mechanism":"Signifor works by binding to somatostatin receptors on the surface of cells, mimicking the natural hormone somatostatin to reduce cortisol production.","indications":["Hypercortisolism"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Recordati Reports Full-Year 2023 Results","summary":"Recordati reported a 10% increase in revenue for the full-year 2023, driven by strong sales of its rare disease treatments.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Recordati Acquires Rights to Develop and Commercialize New Rare Disease Treatment","summary":"Recordati acquired the rights to develop and commercialize a new rare disease treatment from a biotech company.","drugName":"","sentiment":"neutral"},{"date":"2023-06-15","type":"regulatory","headline":"Recordati Receives FDA Approval for New Indication for Existing Product","summary":"Recordati received FDA approval for a new indication for one of its existing products, expanding its use in the treatment of a rare disease.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOVTFOUEJ6R25TQmJOSXJYc1JybURrQ242X0JLaWdxQUtDYnhUcEVDbUdxeS1fOGdJbGE4Z1d1VGZIVHZYaGM2TzBiZElXbnFQcVBvejZVazdnT05tMUdBcTB4V052UnRDTVVlY3B1bzVRY2l5X25JZmlJeUNadnNZZS1iU3pLb2FT?oc=5","date":"2022-01-17","type":"pipeline","source":"Insider Monkey","summary":"Top 15 Most Valuable Italian Companies - Insider Monkey","headline":"Top 15 Most Valuable Italian Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE1xVlJmXzQ3NmRyd3lEYzU1UHNpS2RXa2FqYm5MRUlhT0M1Qy00SlFkSlpfdlBKd21hVDE5UHZJdnlNX2E3b2xKMWxzYk1CMERMNlhvSG5HVURtQTZsZDhfWGRR?oc=5","date":"2020-11-01","type":"pipeline","source":"ChartMill","summary":"REC.MI Stock Price, Quote & Chart | RECORDATI INDUSTRIA CHIMICA (BIT:REC) - ChartMill","headline":"REC.MI Stock Price, Quote & Chart | RECORDATI INDUSTRIA CHIMICA (BIT:REC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPeUNxdzBIQVBVY1gySVBzYlZCM195Znd6Z2xaZlo3a1dleTc5aVI0eU1oQ2c2NHZsLVlZSlJ6ZzlEWXgxOW9YMzZwM1lEM1hXTHE0NE5jR0NBZUlFOUE4S1EyX2xaOWt4d3NEZEJUUXFtLTFFX0RlaFhrN2ctNlEtcTRHSVhNRlFqcXEzaGNYcXZ6OTdUX0ktZEJHcm5UOXRWTXJnNVc2Nkd4V2lkVk5HMzlyVjkzeS16ZzM2NjhFclI?oc=5","date":"2020-03-09","type":"regulatory","source":"bioworld.com","summary":"Competition aplenty as Novartis’ Isturisa is FDA-approved to treat Cushing’s disease - bioworld.com","headline":"Competition aplenty as Novartis’ Isturisa is FDA-approved to treat Cushing’s disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5QRlIyd28takFFekJ2dGd1SUQySk15RlpKVENHWVc4RGI4MkJJaTRta2JZeGdnWHA5c1FxaVRjRURJeVRQRFNFTTE1ZnF2bklyOFBjTg?oc=5","date":"2017-07-05","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE9FM1owY3VILUdmMEh1MlNMUnEzUTVkU1JTUEJFU2JSSl92dklMcG5mNFdkYi1MTldBZWJocC10LVRRa29WekZtU2JnRnlIZFFvVVlzaw?oc=5","date":"2017-05-20","type":"pipeline","source":"Yahoo Finance UK","summary":"Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI) stock price, news, quote and history - Yahoo Finance UK","headline":"Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPNXBWZHc2TzRiSlFSd0M3WGVLRjFLVzkyVV9XWmZaWHZ0eFhWU19jU3l5cXV5VjVKX3phTkpWRmU3RWduU0NGd3ppTWlxREYtRmtPRWxLTWlLZmJTMXp3ZmtrVUtUOHBFcVJjMzlUeVV0VG1pazllYU1oUFNpSEZNRGx3MA?oc=5","date":"2016-07-14","type":"deal","source":"Contract Pharma","summary":"Recordati Acquires Pro Farma AG - Contract Pharma","headline":"Recordati Acquires Pro Farma AG","sentiment":"neutral"}],"patents":[{"drugName":"Plicapon","drugSlug":"plicamycin","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":15600000},{"drugName":"Nuvigil","drugSlug":"armodafinil","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":8,"phaseCounts":{"marketed":8},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Shire","Pfizer","Novartis"],"therapeuticFocus":["Neurology","Cardiology","Endocrinology"],"financials":null,"yahoo":{"currentPrice":49.18,"previousClose":49.12,"fiftyTwoWeekHigh":55.35,"fiftyTwoWeekLow":43.76,"fiftyTwoWeekRange":"43.76 - 55.35","fiftyDayAverage":47.35,"twoHundredDayAverage":50.24,"beta":0.53,"enterpriseValue":12081484800,"forwardPE":13.3,"priceToBook":5.24,"priceToSales":3.82,"enterpriseToRevenue":4.61,"enterpriseToEbitda":12.37,"pegRatio":0,"ebitda":977049024,"ebitdaMargin":37.3,"freeCashflow":584364864,"operatingCashflow":596897024,"totalDebt":2472347904,"debtToEquity":128.8,"currentRatio":1.59,"returnOnAssets":9.4,"returnOnEquity":23.4,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":12,"targetMeanPrice":59.12,"targetHighPrice":71,"targetLowPrice":48,"dividendRate":1.42,"payoutRatio":0.61,"fiveYearAvgDividendYield":2.45,"exDividendDate":1779062400,"insiderHeldPercent":46.8,"institutionHeldPercent":30.7,"sharesOutstanding":203421916,"floatShares":108559979,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":2.12,"epsForward":3.7,"revenuePerShare":12.74,"bookValue":9.39,"officers":[{"age":63,"name":"Dr. Robert  Koremans M.D.","title":"CEO & Director"},{"age":52,"name":"Ms. Cathrin  Petty","title":"Executive Director"},{"age":56,"name":"Mr. Giampiero  Mazza","title":"Executive Director"},{"age":53,"name":"Mr. Michael  McClellan","title":"Chief Financial Officer"},{"age":null,"name":"Ms. Eugenia Shen Litz","title":"VP & Head of Investor Relations"},{"age":null,"name":"Ms. Bibianne  Bon","title":"Group Chief Legal Officer"},{"age":null,"name":"Ms. Laura  Conti","title":"Group Communications Director"},{"age":null,"name":"Mr. Gabriele  Finzi","title":"Executive VP of Corporate Development, Licensing & Innovation"}],"industry":"Drug Manufacturers - General","irWebsite":"","website":"https://recordati.com","phone":"39 02 487871"}}